Zofra ODT 8mg 10pcs

Indications

An antiemetic drug called Zofra ODT 8 is frequently used to treat nausea and vomiting brought on by conditions like stomach upset. Additionally, it is used to stop nausea and vomiting brought on by radiotherapy, chemotherapy, or any other type of surgery. With or without food, Zofra ODT 8 may be taken either on its own or in combination with other medications. Depending on what you are taking it for, your doctor will advise you on the appropriate dosage. Usually, the first dose is taken prior to the start of the operation, the chemotherapy, or the radiotherapy. After these therapies, follow your doctor's instructions for any additional dosages.

Pharmacology

The 5HT3 receptor is effectively and highly specifically blocked by ondansetron. The unknown is the exact mechanism of action it uses to treat nausea and vomiting. Chemotherapeutic drugs and radiotherapy may stimulate the release of 5HT in the small intestine by stimulating vagal afferents via 5HT3 receptors, resulting in a vomiting reflex. The beginning of this response is prevented by ondansetron. The region postrema, which is on the floor of the fourth ventricle, may release 5HT as a result of vagal afferent activation, which would then encourage emesis through a central mechanism. The most likely explanation for ondansetron's ability to treat nausea and vomiting brought on by cytotoxic chemotherapy and radiotherapy is that it inhibits 5HT3 receptors on peripheral and central nervous system neurons.

There may be similarities between cytotoxic-induced nausea and vomiting and postoperative nausea and vomiting, despite the fact that the mechanisms of action are unknown.

Dosage & Administration

Chemotherapy-Induced Vomiting and Nausea

Adults, children (6 months to 18 years old):

• Three doses of 0.15 mg/kg, up to a maximum of 16 mg per dose, for an 8 mg tablet or orodispersible tablet.

Radiotherapy-Induced Nausea and Vomiting-

Adults:

A tablet orally disintegrates in 8 mg: 8 mg orally at the beginning, 1 to 2 hours prior to radiotherapy. For up to 5 days following a course of radiotherapy, take 8 mg orally every 8 hours.

Postoperative Nausea and Vomiting-

Adults:

• 16 mg is administered as two 8 mg tablets in the form of an 8 mg tablet.

Interaction

Ondansetron appears to have a low risk of clinically significant drug interactions.

Contraindications

Patients with known hypersensitivity to the drug or any of its components should not take it. Apomorphine is being taken at the same time.

Side Effects

The most frequent side effects associated with chemotherapy-induced nausea and vomiting (incidence: 7%) are diarrhea, headaches, and fever. The most frequent postoperative nausea and vomiting adverse reaction in adults is headache (10% incidence), whereas the most prevalent adverse reaction in pediatric patients aged 1 to 24 months is diarrhea (incidence 2 percent ).

Pregnancy & Lactation

Pregnancy Classification B. Ondansetron is excreted by rats in their milk. Ondansetron is not known to be excreted in human milk. Ondansetron should be administered with caution to a nursing woman because many drugs are excreted in human milk.

Precautions & Warnings

With or without known hypersensitivity to other selective 5-HT3 receptor antagonists, hypersensitivity reactions such as anaphylaxis and bronchospasm have been reported. The lengthening of the QT interval is dose-dependent.

Storage Conditions

Keep the temperature below 30°C and away from light and moisture. Keep out of children's reach.